Cargando…
Serum IL-6 and procalcitonin are two promising novel biomarkers for evaluating the severity of COVID-19 patients
To evaluate the development of coronavirus disease 2019 (COVID-19), the roles of interleukin 6 (IL-6) and procalcitonin (PCT) were assessed to diagnose severe COVID-19. Between January and February 2020, 100 consecutive patients with confirmed COVID-19 were included and divided into common (n = 56),...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183731/ https://www.ncbi.nlm.nih.gov/pubmed/34087864 http://dx.doi.org/10.1097/MD.0000000000026131 |